Petros Plots Next Point On OTC ED Switch Path: Stendra Self-Selection Study

Two weeks after announcing strong results from label comprehension study, initiating self-selection study using Drug Facts label tested for nonprescription sales of its ED drug Stendra.

• Source: Shutterstock

Petros Pharmaceuticals Inc. is ensuring that investors as well as other interested parties know about each point of progress in its program targeting launching the first erectile dysfunction drug available OTC in the US.

Two weeks after announcing strong results from a label comprehension study, it’s initiating a self-selection study using the Drug Facts...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Rx-to-OTC Switch

More from Health